for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biotest AG

BIOG.DE

Latest Trade

33.80EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

20.80

 - 

34.70

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
33.80
Open
--
Volume
--
3M AVG Volume
0.03
Today's High
--
Today's Low
--
52 Week High
34.70
52 Week Low
20.80
Shares Out (MIL)
39.57
Market Cap (MIL)
1,347.41
Forward P/E
-57.50
Dividend (Yield %)
--

Next Event

Q2 2021 Biotest AG Earnings Release

Latest Developments

More

Biotest Q1 Loss After Taxes Widens To EUR 14.1 Million

Biotest: Good Tolerability And Efficacy Of Intratect In Primary And Secondary Immunodeficiencies In Study

Biotest FY Loss After Tax At EUR -31.4 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biotest AG

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Industry

Biotechnology & Drugs

Contact Info

Landsteinerstr. 5

63303

Germany

+49.6103.8010

https://www.biotest.com/

Executive Leadership

Rolf K. Hoffmann

Chairman of the Supervisory Board

Michael Ramroth

Chairman of the Management Board, Chief Executive Officer/Chief Financial Officer

Tan Yang

Deputy Chairman of the Supervisory Board

Martin Moeller

Group Finance and Treasury Officer

Georg Floss

Chief Operating Officer, Member of the Management Board

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.4K

2020

0.5K

2021(E)

0.5K
EPS (EUR)

2018

-0.320

2020

-0.800

2021(E)

-0.600
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.66
Price To Book (MRQ)
3.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
110.40
LT Debt To Equity (MRQ)
108.42
Return on Investment (TTM)
-3.46
Return on Equity (TTM)
-3.09

Latest News

Latest News

BRIEF-Biotest Announces First Sales Of Human Albumin In China

* SUCCESSFULLY ENTERS CHINA, THE WORLD'S BIGGEST HUMAN ALBUMIN MARKET

BRIEF-Biotest: Zutectra Demonstrates Improved Quality Of Life In Study With Liver Transplant Patients

* BIOTEST'S ZUTECTRA(R) DEMONSTRATES IMPROVED QUALITY OF LIFE IN A STUDY WITH LIVER TRANSPLANT PATIENTS

BRIEF-Biotest Completes Phase I/III Clinical Trial With Fibrinogen

* ACHIEVES SIGNIFICANT MILESTONE BY COMPLETING PHASE I/III CLINICAL TRIAL WITH FIBRINOGEN

BRIEF-Biotest Q1 EBIT Up At EUR 1.4 Mln

* Q1 EBIT IMPROVED OVER PRIOR-YEAR PERIOD BY EUR 11.3 MILLION AND REACHED EUR 1.4 MILLION IN FIRST THREE MONTHS OF 2020

BRIEF-Polygon Says Requests Special Audit At Biotest AG

Polygon Says Requests Special Audit At Biotest AG:

BRIEF-4Sc: FDA Accepts IND Application For MERKLIN 2 Study

* INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR DOMATINOSTAT IN COMBINATION WITH AVELUMAB (BAVENCIO(R)) HAS BEEN ACCEPTED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Biotest Says It Is Working On Drug Against COVID-19

* PRODUCES LIFE-SAVING MEDICINE DERIVED FROM PLASMA FROM HEALED COVID-19 PATIENTS AND PARTICIPATES IN A CROSS-INDUSTRY INITIATIVE

BRIEF-Biotest FY Loss After Tax Narrows To EUR 4.7 Million

* FY SALES FROM CONTINUING OPERATIONS 419.1 MILLION EUR VERSUS 400.3 MILLION EUR YEAR AGO

BRIEF-Biotest AG FY EBIT Turns To Loss Of EUR 1.2 Million

* FY EBIT LOSS -1.2 MILLION EUR VERSUS 10.6 MILLION EUR PROFIT YEAR AGO

BRIEF-Aryzta Q1 Reported Revenue Down 2.1% To EUR 843.9 Million

* FY19 ESTABLISHED FOUNDATIONS ON OUR PATH TOWARDS STABILITY, PERFORMANCE AND GROWTH AND Q1 FY20 REVENUE HAS PERFORMED IN LINE WITH OUR EXPECTATIONS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up